CGA alleviates liver inflammation during non-alcoholic steatohepatitis (NASH) progression by blocking the LPS-TLR4-MyD88 signaling pathway via direct binding to MyD88 and by activation of Nrf2/PPARα signaling [173]. Here, NFE2L2 is linked to metabolic dysfunction-associated steatohepatitis.